YOU ARE EXPLORING
Oncology Biomarkers PD-L1
Cancer biomarkers | From findings to interpretation

PD-L1

PD-L1 immunohistochemistry for selected immunotherapy regimens, with emphasis on assay, scoring method, and indication-specific thresholds.

Clinical context

Biomarker definition and clinical relevance

PD-L1 is a protein biomarker most often assessed by immunohistochemistry on FFPE tumor tissue. Antibody clone, platform, scoring approach, cancer type, and treatment regimen affect interpretation. Tumor proportion score (TPS) and combined positive score (CPS) are different metrics and cannot be directly converted.

Note for clinicians

Final decisions depend on tumor type, stage, previous therapy, a validated assay result, and current drug indications. This content does not imply availability of a bookable laboratory service.

CLINICAL APPLICATIONS

Clinical applications and result interpretation

01

Advanced NSCLC and immunotherapy eligibility

PD-L1 TPS informs some PD-1/PD-L1 treatment decisions in NSCLC. Depending on the drug and regimen, thresholds such as TPS ≥1% or ≥50% may apply, but oncogenic drivers, line of therapy, and disease setting remain essential.

Assay and specimen: Indication-appropriate validated PD-L1 IHC, controlled clone/platform, and tumor membrane staining reported as TPS among viable tumor cells.

Clinical interpretation: Current ASCO guidance requires appropriate molecular-driver testing; PD-L1 expression alone is not sufficient for selecting initial NSCLC therapy.

02

Other malignancies and CPS scoring

For selected gastric/GEJ, cervical, head and neck and other cancers, certain drug indications use CPS. Thresholds vary across indications and may change with revised labeling.

Assay and specimen: Use the specified companion assay and report CPS according to the standardized tumor-cell and immune-cell scoring protocol.

Clinical interpretation: TPS is the percentage of positive tumor cells. CPS is positive eligible tumor and immune cells divided by viable tumor cells, multiplied by 100 (capped at 100).

03

Biologic and sampling limitations

Spatial and temporal heterogeneity, prior treatment, primary versus metastatic site, and small biopsy size can alter apparent PD-L1 status.

Assay and specimen: Document specimen type, sufficient viable tumor cells, clone, assay, controls, and fixation conditions.

Clinical interpretation: PD-L1 positivity does not guarantee benefit, and negativity does not exclude benefit under every immunotherapy regimen.

INTERPRETATION / LIMITATIONS

Limitations and interpretive notes

• Use the cancer-, drug-, and assay-specific threshold; do not apply one universal cutoff.

• PD-L1 is primarily an IHC assay and cannot be directly replaced by NGS.

• PD-L1 must be interpreted alongside other biomarkers and the overall clinical context.

REFERENCES

Guidelines and references

Discuss a specific molecular scenario

For questions about a clinical scenario, use the support form without including any patient identifiers.

Specialist support form →
WhatsAppCall usGet expert consultation